BMS-708163, also known as Avagacestat, is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. It was designed to selectively inhibit the production of amyloid-beta (Aβ) peptides, which are believed to play a key role in the development of AD, while minimizing the impact on Notch signaling, a pathway crucial for various cellular processes.